INVIMA Guide
INVIMA regulatory translation requirements.
A technical guide to the linguistic, certification, and formatting rules Colombia's Instituto Nacional de Vigilancia de Medicamentos y Alimentos applies to clinical trial translation for drug and device submissions — and why general-purpose machine translation creates avoidable requerimientos in first-cycle review.
Published July 2026
The context
Colombia reviews in Spanish, and reviews it carefully.
INVIMA is the national authority for medicines, biologics, medical devices, and clinical research in Colombia. Every clinical trial authorization, protocol amendment, and sanitary registration dossier is reviewed in Spanish. Source documents in English or another language are accepted only with a translation that meets Colombia's formal requirements. Anything less generates an auto de requerimiento, and each clarification resets the review clock.
For U.S. and European sponsors, this is easy to underestimate. Colombian regulatory Spanish is not interchangeable with other regional variants, and INVIMA has specific expectations for how medical terms, statistical language, and legal attestations are rendered. A translation that is fluent but not regulator-ready is the most common source of first-cycle delay.
What must be translated
The documents that move a Colombia submission.
For a clinical trial authorization, INVIMA expects Spanish translations of the protocol, informed consent form, investigator's brochure, case report forms, and serious adverse event / SUSAR narratives. Device trials add instructions for use, risk analysis, and biocompatibility summaries. For sanitary registration, the list expands to include labeling, CMC sections, stability data, GMP certificates, and Certificates of Pharmaceutical Product (CPP).
Each document must be complete. Partial translations, translated body text with untranslated appendices, or omitted footnotes are treated as incomplete submissions. INVIMA reviewers compare the Spanish translation against the source document line by line in disputed areas, so the two versions must match exactly in structure and numbering.
Certification
INVIMA expects more than a bilingual page.
Colombian regulatory submissions typically require translations to be performed by a certified translator recognized by the Ministry of Foreign Affairs of Colombia. The certification must include the translator's full name, credentials, resolution number where applicable, signature, and date, along with a statement that the translation is accurate and complete.
Foreign-issued legal instruments — powers of attorney, corporate resolutions, GMP certificates, and Certificates of Pharmaceutical Product — generally require an apostille under the Hague Convention (Colombia is a signatory) before they can be presented to INVIMA. When the source language is not Spanish, an accompanying certified translation is required. The safest default is to prepare a certified translation for every clinical and regulatory document and to apostille any foreign public document used as a legal instrument.
Where translations fail
The four most common sources of INVIMA queries.
- Terminology mismatches. General-purpose translation engines often map English clinical terms to Peninsular or non-Colombian Spanish. INVIMA reviewers expect Colombian regulatory usage and will flag deviations even when they are technically understandable elsewhere.
- Missing apostilles on foreign instruments. Powers of attorney, GMP certificates, and CPPs submitted without a valid apostille are rejected on a paperwork basis, regardless of translation quality.
- Missing certificates or signatures. Translations submitted without the translator's credentials, resolution number, or with cut-off signatures or dates are rejected. This is a paperwork failure, not a linguistic one, but it costs the same amount of time.
- Inconsistent drug or device nomenclature. If a product is referred to by three different names across the protocol, informed consent, and IFU, INVIMA will ask for a harmonized version. Controlled vocabulary is not optional.
How we cover this
The First-Pass Acceptance Program for Colombia.
Our clinical trial translation service pairs private-inference translation with medical review by clinicians who understand Colombian regulatory Spanish, then routes legal instruments to certified Colombian translators and coordinates apostille handling before the dossier is assembled. The output is a Spanish submission package aligned to INVIMA's expectations — not a generic translation.
We back it with a written SLA: zero critical errors on delivery, or we re-issue at no cost and credit $2,500 per business day of delay (Tier 1-A). For INVIMA submissions, that credit is priced against the actual cost of a delayed clinical trial authorization or a late sanitary registration.
What "specialized" actually means
Clinical trial translation services are a regulatory discipline, not a language service.
A specialized workflow pairs machine-assisted translation with medical review by clinicians who read the local regulatory guidance for a living. The platform compresses time. The medical reviewer preserves clinical and regulatory intent. Neither one alone is a substitute for the other, and the Colombia-market outcome depends on both being present.
For a deeper look at where general-purpose AI translation falls short in Phase III documentation, read our comparison of AI vs. medical review accuracy.
Related resources
Continue reading across the LatAm regulatory stack.
Clinical Trial Translation Services hub
The Amavita overview of LatAm regulator coverage, MD-led review, and the First-Pass Acceptance SLA.
Read more →COFEPRIS translation requirements (Mexico)
Mexican Spanish submission rules, perito tradutor requirements, and common requerimientos.
Read more →ANVISA translation requirements (Brazil)
Portuguese submission rules, tradutor público juramentado requirements, and common exigências.
Read more →LatAm market access impact
How translation quality shapes the speed of market clearance and audit success across Latin America.
Read more →Ready to move a Colombia program? Start an INVIMA pilot with Amavita →
Next step
Move a Colombia program through the workflow.
Tell us about an INVIMA submission or Colombia clinical trial on your calendar. Our team will reach out within 2 business days with a scoped pilot proposal.